Drug intelligence / Profile preview

ODT-104

Development stage: Unknown
Lead developer: Odyssey Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

ODT-104 is an orally bioavailable, selective small molecule inhibitor of Janus kinase 1 (JAK1) being developed by Odyssey Therapeutics. It is designed to treat autoimmune and inflammatory diseases by selectively blocking the JAK1 signaling pathway, which is involved in the production of pro-inflammatory cytokines, while minimizing the inhibition of other JAK isoforms like JAK2 to reduce potential side effects such as anemia or neutropenia. The drug is currently in clinical development, with a primary focus on conditions such as atopic dermatitis and other inflammatory disorders.

Targets

JAK1 (Janus kinase 1)

Beyond the preview

Go deeper on ODT-104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ODT-104.

Explore the full profile